Quantitative measurement of SMRPs will be done by two-step immunoassay on human serum using enzyme immunoassay technology with colorimetric detection in a standard sandwich ELISA
format. Two monoclonal antibodies are used, one for capture and the other for detection. Sera will be sent to the NYU biomarker labor
atory and also measured for SMRP in within one month to compare with the levels in found in Chile. Osteopontin and fibulin-3 will be measured in plasma samples, following manufacturer
specifications similar to those used for SMRPs.
HMGB1 will also be measured by standard ELISA
Lung and Upper Aerodigestive Cancers Research Group
A prospective study to evaluate the utility of various biomarkers in the context of an MM Early
Detection Program. The study cohort will be composed of workers at a company
with known asbestos exposure. Historically, a considerable number of workers at this company have
Determine whether serial determination of
osteopontin, mesothelin and fibulin-3, and HMGB1
in plasma samples can be used as biomarkers
[sic] for early detection of MM in high-risk
Determine the utility of measuring levels of t
hese biomarkers in pleural fluid samples from
patients who develop
Determine the utility of these biomarkers
for monitoring MM patients undergoing different
Create a plasma/serum/PAXgene/DNA sample
"bank" that can be used for genetic and
biomarker studies by researchers at participating
institutions or other
Assuming 300-375 participants, a 0.5-1.0% per year incidence rate of MM, and three years of
follow-up per participant, we project 4-11 incident cases of MM over the course of the study. This sample size will provide insufficient
power to build and test models combining multiple markers. The study will have low power but will have the benefits of having a ProBE design with the ability to examine the time course of mark
ers and their prognostic ability to detect MM prior to detection via chest CT scan. The performance of the individual markers (SMRP, osteopontin, fibulin-3, and HMGB1) at the time of a chest CT scan will be assessed by ROC curves. Blood measurements taken at a time that there is not a concurrent chest CT scan (e.g., mid-year blood draws without an 17 actionable SMRP level for which there would be no protocol-specified chest CT scan) will not be included in this analysis. The prognostic ability of markers will be assessed by ROC curves using marker values one or two years prior to the time of diagnosis of MM.
For each marker, we will produce a plot of the ti
me course of the marker for each individual
with the time courses for cases of MM highlighted and the time of MM detection indicated, to develop
hypotheses about the time course of marker values prior to MM detection, which in turn can be used
to develop alternative marker decision rules (e.g
., based on SMRP trajectory) that incorporate
longitudinal marker values. This analysis will be exploratory.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
Thank you to everyone who contributed to the successful and productive EDRN Orientation Meeting in October. The next EDRN Steering Committee Meeting will take place in March 6-9, 2017 in Tempe, AZ. More information about this meeting will be available soon.